专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明授权

US08877510B2 Method for conducting platelet aggregation analysis 有权
标题翻译：进行血小板聚集分析的方法
公开(公告)号：US08877510B2
公开(公告)日：2014-11-04
申请号：US14087823
申请日：2013-11-22
申请人： F. Hoffmann-La Roche AG
发明人： Andreas Calatzis , Ben Krüger , Marc Wittwer
IPC分类号： G01N33/86 , G01N33/48 , G01N27/02 , G01N33/49 , G01N27/07
CPC分类号： G01N33/86 , G01N27/07 , G01N33/4905
摘要： A cartridge device having a receiving portion for receiving a blood sample and a jack portion for receiving a plug; a stirring device for circulating the blood sample within the receiving portion; and an electrode holder having at least one incorporated electrode wire pair; wherein the electrode holder is attachable to the cell such that one end of the at least one electrode wire pair forms a sensor unit for measuring the electrical impedance between the two electrode wires of the at least one electrode wire pair within the blood sample and that the opposite end of the at least one electrode wire pair forms a plug portion being connectable directly to the plug for an electrical connection of the sensor unit to an analyzer.
摘要翻译：具有用于接收血液样本的接收部分和用于接收插头的插座部分的盒装置; 搅拌装置，用于在接收部分内循环血液样品; 和具有至少一个结合的电极线对的电极保持器; 其中所述电极保持器可附接到所述电池，使得所述至少一个电极线对的一端形成传感器单元，用于测量所述血液样本内的所述至少一个电极线对的两个电极线之间的电阻抗，至少一个电极线对的相对端形成可直接连接到插头的插头部分，用于传感器单元与分析器的电连接。

82. 发明申请

US20140314748A1 ANTIBODY FORMULATIONS 审中-公开
标题翻译：抗体配方
公开(公告)号：US20140314748A1
公开(公告)日：2014-10-23
申请号：US14207885
申请日：2014-03-13
申请人： F. Hoffmann-La Roche AG , Genentech, Inc.
发明人： Yatin GOKARN , Isidro E. ZARRAGA , Jonathan ZARZAR , Thomas PATAPOFF , Christine WURTH
IPC分类号： A61K47/26 , A61K39/395
CPC分类号： A61K47/26 , A61K9/08 , A61K39/39591 , C07K16/22 , C07K16/2887
摘要： The invention provides stable aqueous pharmaceutical formulations comprising a therapeutic antibody, trehalose, a buffer, and optional surfactant, and having a pH in the range of about 5.5 to about 7.0. The invention also provides methods for making such formulations and methods of using such formulations.
摘要翻译：本发明提供了包含治疗性抗体，海藻糖，缓冲液和任选的表面活性剂，并且具有约5.5至约7.0范围内的pH的稳定的含水药物制剂。本发明还提供了制备这些制剂的方法和使用这些制剂的方法。

83. 发明授权

US08846762B2 Benzopyran and benzoxepin PI3K inhibitor compounds and methods of use 有权
标题翻译：苯并吡喃和苯并辛菌素PI3K抑制剂化合物及其使用方法
公开(公告)号：US08846762B2
公开(公告)日：2014-09-30
申请号：US13738846
申请日：2013-01-10
申请人： Genentech, Inc. , F. Hoffmann—La Roche AG
发明人： Steven Do , Richard Goldsmith , Tim Heffron , Aleksandr Kolesnikov , Steven Staben , Alan G. Olivero , Michael Siu , Daniel P. Sutherlin , Bing-Yan Zhu , Paul Goldsmith , Tracy Bayliss , Adrian Folkes , Neil Pegg
IPC分类号： A01N37/00 , C07D333/00 , A61K31/4365 , A61K31/4196 , A61K31/53 , C07D495/04 , A61K31/496 , A61K31/427 , A61K31/429 , A61K31/4155 , C07D495/14 , A61K31/4245 , A61K31/4436 , C07D513/14 , A61K31/381
CPC分类号： C07F5/02 , A61K31/381 , A61K31/4155 , A61K31/4196 , A61K31/4245 , A61K31/427 , A61K31/429 , A61K31/4365 , A61K31/4436 , A61K31/496 , A61K31/53 , C07D495/04 , C07D495/14 , C07D513/14
摘要： Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomer solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formulas I and II for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
摘要翻译：式I和II的苯并吡喃和苯并氧杂环己酮化合物，包括立体异构体，几何异构体，互变异构体溶剂合物，代谢物和药学上可接受的盐，可用于抑制脂质激酶，包括p110α和PI3K的其他同种型，并用于治疗疾病如癌症介导通过脂质激酶。公开了使用式I和II的化合物在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。

84. 发明申请

US20140194476A1 PYRIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELORIATION OR PREVENTION OF A VIRAL DISEASE 审中-公开
标题翻译：吡咯烷酮衍生物及其在治疗，预防或预防病毒性疾病中的应用
公开(公告)号：US20140194476A1
公开(公告)日：2014-07-10
申请号：US14149218
申请日：2014-01-07
申请人： Savira pharmaceuticals GmbH , European Molecular Biology Laboratory , F. Hoffmann-La Roche AG
发明人： Andrea Wolkerstorfer , Oliver Szolar , Norbert Handler , Helmut Buschmann , Stephen Cusack , Mark Smith , Sung-Sau So , Ronald Charles Hawley
IPC分类号： C07D213/81 , C07D213/79 , A61K31/4412 , A61K45/06
CPC分类号： C07D213/81 , A61K31/4412 , A61K45/06 , C07D213/78 , C07D213/79
摘要： The present invention relates to a compound having the general formula (II), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
摘要翻译：本发明涉及具有通式（II）的化合物，其任选呈药学上可接受的盐，溶剂合物，多晶型物，共轭，共结晶，前体药物，互变异构体，外消旋物，对映体或非对映异构体或其混合物的形式，其是有用的治疗，预防或预防病毒性疾病。此外，公开了具体的组合疗法。

85. 发明申请

US20140194432A1 NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE 审中-公开
标题翻译：萘啶酮衍生物及其在治疗，改善或预防病毒性疾病中的应用
公开(公告)号：US20140194432A1
公开(公告)日：2014-07-10
申请号：US14149381
申请日：2014-01-07
申请人： Savira pharmaceuticals GmbH , F. Hoffmann-La Roche AG , European Molecular Biology Laboratory
发明人： Andrea Wolkerstorfer , Oliver Szolar , Norbert Handler , Helmut Buschmann , Stephen Cusack , Mark Smith , Sung-Sau So , Ronald Charles Hawley , Achyutharao Sidduri
IPC分类号： C07D471/04 , A61K31/4375 , A61K31/4985 , A61K45/06
CPC分类号： A61K31/519 , A61K31/4375 , A61K31/4985 , A61K31/513 , A61K45/06 , C07D401/04 , C07D471/02 , C07D471/04
摘要： The present invention relates to a compound having the general formula (V), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
摘要翻译：本发明涉及具有通式（Ⅴ）的化合物，其任选呈药学上可接受的盐，溶剂化物，多晶型物，副产物，共结晶，前体药物，互变异构体，外消旋物，对映体或非对映体或其混合物的形式，它们是有用的治疗，预防或预防病毒性疾病。此外，公开了具体的组合疗法。

86. 发明申请

US20020142333A1 Thermostable DNA polymerases incorporating nucleoside triphosphates labeled with fluorescein family dyes 审中-公开
标题翻译：掺有荧光素家族染料标记的核苷三磷酸的热稳定DNA聚合酶
公开(公告)号：US20020142333A1
公开(公告)日：2002-10-03
申请号：US10052417
申请日：2002-01-17
申请人： F. Hoffmann-La Roche AG.
发明人： David Harrow Gelfand , Lisa Vivian Kalman , Fred Lawrence Reichert , Christopher Lim Sigua , Thomas W. Myers
IPC分类号： C12Q001/68 , C12P019/34 , C12N009/22
CPC分类号： C12N9/1252
摘要： Modified thermostable DNA polymerases having enhanced efficiency for incorporating unconventional nucleotides such as those labeled with fluorescein family dyes are advantageous in many in vitro DNA synthesis applications. Such enzymes are particularly useful for use in chain termination nucleic acid sequencing protocols, as are native forms of such enzymes. Genes encoding the modified enzymes and methods for their production and use offer cost and efficiency advantages for DNA sequencing.
摘要翻译：具有提高非常规核苷酸效率的修饰的耐热性DNA聚合酶，例如用荧光素家族染料标记的那些核苷酸，在许多体外DNA合成应用中是有利的。这样的酶特别可用于链终止核酸测序方案，以及这些酶的天然形式。编码修饰酶的基因及其生产和使用方法为DNA测序提供了成本和效率优势。

87. 发明公开

US20240285643A1 TREATING INFLUENZA USING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF IN A SUBJECT HAVING INFLUENZA AND A SEVERE INFLUENZA CONDITION 审中-公开
公开(公告)号：US20240285643A1
公开(公告)日：2024-08-29
申请号：US18602656
申请日：2024-03-12
申请人： Shionogi & Co., Ltd. , F. HOFFMANN-LA ROCHE AG
发明人： Takeki UEHARA , Toru ISHIBASHI , Takao SHISHIDO , Keita FUKAO , Motoyasu OONISHI , Barry CLINCH , Jaspinder RANDHAWA
IPC分类号： A61K31/5383 , A61K31/215 , A61P31/16
CPC分类号： A61K31/5383 , A61K31/215 , A61P31/16
摘要： A method for treating an influenza virus infection is described. The disclosed method generally involves administering an effective amount of a compound (A), for example baloxavir marboxil, and a compound (B), for example a neuraminidase inhibor, to a subject that (1) has an influenza virus infection, (2) has been symptomatic of the influenza virus infection for no more than 96 hours, and (3) further has at least one severe influenza condition selected from the following: (a) being hospitalized due to severe influenza virus infection, (b) requiring an extension of hospitalization because of the influenza virus infection during the hospitalization, (c) having a National Early Warning Score 2 of four or more, (d) being on support for respiration, and (e) having at least one complication attributable to the influenza virus infection that necessitates hospitalization.

88. 发明公开

US20240279312A1 COMPOSITION COMPRISING RECOMBINANT Gplba RECEPTOR PROTEIN 审中-公开
公开(公告)号：US20240279312A1
公开(公告)日：2024-08-22
申请号：US18353623
申请日：2023-07-17
申请人： F. HOFFMANN-LA ROCHE AG
发明人： Elizabeth Booth , Virginia Montanini , John A. Hall , Jody Berry
IPC分类号： C07K14/745 , C07K14/705
CPC分类号： C07K14/745 , C07K14/705 , C07K2317/92 , C07K2319/02 , C07K2319/21 , C07K2319/30
摘要： Composition comprising recombinant Gplbα receptor protein
Various aspects of the invention relate to recombinant polypeptides that specifically bind human von Willebrand Factor. Such recombinant polypeptides typically include a modified extracellular domain of platelet glycoprotein Ibα that typically comprises at least one mutation selected from G233T, D235V, and K237V, and such recombinant polypeptides optionally include an oligomerization domain.

89. 发明公开

US20240052058A1 METHODS OF USING A BISPECIFIC ANTIBODY THAT RECOGNIZES COAGULATION FACTOR IX AND/OR ACTIVATED COAGULATION FACTOR IX AND COAGULATION FACTOR X AND/OR ACTIVATED COAGULATION FACTOR X 审中-公开
公开(公告)号：US20240052058A1
公开(公告)日：2024-02-15
申请号：US18466900
申请日：2023-09-14
申请人： Chugai Seiyaku Kabushiki Kaisha , F. Hoffmann-La Roche AG
发明人： Koichiro Yoneyama , Christophe Schmitt
IPC分类号： C07K16/36 , A61P7/04
CPC分类号： C07K16/36 , A61P7/04 , C07K2317/24 , C07K2317/31 , C07K2317/94 , A61K2039/545
摘要： An objective of the present invention is to provide an effective pharmaceutical composition or a dosage regimen for preventing and/or treating bleeding, a disease accompanying bleeding, or a disease caused by bleeding. The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes (a) blood coagulation factor IX and/or activated blood coagulation factor IX and (b) blood coagulation factor X and/or activated blood coagulation factor X according to a given dosage regimen, bleeding, a disease accompanying bleeding, or a disease caused by bleeding can be prevented and/or treated more effectively.

90. 发明公开

US20240025987A1 USE OF ANTI-IL-27 ANTIBODIES 审中-公开
公开(公告)号：US20240025987A1
公开(公告)日：2024-01-25
申请号：US18201626
申请日：2023-05-24
申请人： SURFACE ONCOLOGY, INC. , F. HOFFMANN-LA ROCHE AG
发明人： Alison O'NEILL , Lauren HARSHMAN , Jonathan HILL , Jou-Ku CHUNG , Kerry WHITE , Robert ROSS
IPC分类号： C07K16/24 , C07K16/22 , C07K16/28 , A61P35/00
CPC分类号： C07K16/244 , C07K16/22 , C07K16/2827 , A61P35/00 , A61K2039/507
摘要： The present disclosure relates to methods of treating cancer comprising administering to a subject an anti-IL-27 antibody, atezolizumab, and bevacizumab.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式